Skip to main content
. 2022 Mar 30;37(4):483–494. doi: 10.46497/ArchRheumatol.2022.8221

Table 7. Convergent validity results.

  PEST
  r *p
CASPAR 0.455 <0.001
ToPAS 2 0.763 <0.001
PEST: Psoriasis Epidemiology Screening Tool; CASPAR: Classification Criteria for Psoriatic Arthritis; ToPAS 2: Toronto Psoriatic Arthritis Screen 2; r: Spearman’s rho coefficient; * p<0.05, statistically significant.